This comparison breaks down pricing, clinician support, and delivery speed so adults can match the best remote GLP-1 option to their needs
Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation
Healthcare providers may only recommend GLP-1 receptor agonists when BMI is over 30 (i.e., obesity), or if BMI is over 27 and the patient has an associated health condition, such as diabetes, kidney disease, or obstructive sleep apnea
In the previous decision regarding Ozempic, as an example, the benefit limitations were not stated as referring to the treatment of T2DM, even though this was the only medical condition mentioned in the investigation
Both involve subcutaneous injection into the abdomen, thigh, or upper arm